Safety Concerns Lead EMA Panel To Nix Kynamro and Fanapt

Clinical Trials Advisor
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against approval of Genzyme and Isis Pharmaceuticals’ familial hypercholesterolemia drug Kynamro and Vanda Pharmaceuticals’ schizophrenia treatment Fanapt, citing safety issues with both.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00